GlassScriptPhysician profile
Steven Keith Snyder
NPI 1427053149
$1,495.99
in general payments reported to CMS, 2019-2025
17 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $73.58 · 2021: $265 · 2022: $228 · 2023: $351 · 2024: $174 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.90 | 2022-2024 | Durysta, Lumigan |
| Mallinckrodt Hospital Products INC. | $218.98 | 2021-2024 | Acthar |
| Dompe US, INC. | $156.45 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $107.74 | 2019-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.48 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $93.81 | 2019-2024 | |
| Oyster Point Pharma, INC. | $75.05 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $69.79 | 2021-2025 | Hydrus Microstent |
| Rxsight INC | $62.67 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $55.85 | 2023-2024 | Vyzulta, Prolensa, Scoutpro Osmolarity System |
| Aerie Pharmaceuticals, INC. | $48.69 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $40.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.94 | 2019-2022 | |
| Biotissue Holdings INC. | $32.05 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $28.53 | 2024 | Xdemvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $19.07 | 2019 | |
| Allergan, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.